0 14 Identification identification NN 15 17 of of IN 18 20 an an DT 21 42 ionomycin/cyclosporin ionomycin/cyclosporin NN 43 55 A-responsive a-responsive JJ 56 63 element element NN 64 70 within within IN 71 74 the the DT 75 80 human human JJ 81 82 T t NN 83 87 cell cell NN 88 96 receptor receptor NN 97 102 gamma gamma NN 103 111 enhancer enhancer NN 111 112 . . . 114 124 Activation Activation NNP 125 132 through through IN 133 136 the the DT 137 153 Ca2+/calcineurin Ca2+/calcineurin NNP 154 161 pathway pathway NN 162 164 is be VBZ 165 174 essential essential JJ 175 177 to to TO 178 181 the the DT 182 195 transcription transcription NN 196 198 of of IN 199 203 many many JJ 204 212 cytokine cytokine NN 213 218 genes gene NNS 218 219 . . . 220 223 The the DT 224 233 conserved conserve VBN 234 244 cis-acting cis-acting JJ 245 253 sequence sequence NN 253 254 , , , 255 261 GGAAAA GGAAAA NNP 261 262 , , , 263 266 and and CC 267 280 transcription transcription NN 281 288 factors factor NNS 289 296 binding bind VBG 297 299 to to TO 300 304 this this DT 305 313 sequence sequence NN 314 317 are be VBP 318 326 involved involve VBN 327 329 in in IN 330 333 the the DT 334 342 response response NN 343 345 to to TO 346 355 increased increase VBN 356 369 intracellular intracellular JJ 370 374 Ca2+ ca2+ NN 375 389 concentrations concentration NNS 389 390 . . . 391 395 Here here RB 396 398 we we PRP 399 405 report report VBP 406 409 the the DT 410 424 identification identification NN 425 428 and and CC 429 439 importance importance NN 440 442 of of IN 443 446 the the DT 447 451 same same JJ 452 460 sequence sequence NN 461 463 in in IN 464 465 a a DT 466 478 non-cytokine non-cytokine JJ 479 483 gene gene NN 483 484 , , , 485 488 the the DT 489 494 human human JJ 495 496 T t NN 497 501 cell cell NN 502 510 receptor receptor NN 511 516 gamma gamma NN 517 518 ( ( ( 518 522 TCRG TCRG NNP 522 523 ) ) ) 524 532 enhancer enhancer NN 532 533 . . . 534 541 Results result NNS 542 546 from from IN 547 560 site-directed site-directed JJ 561 570 mutations mutation NNS 571 574 and and CC 575 590 electrophoretic electrophoretic JJ 591 599 mobility mobility NN 600 605 shift shift NN 606 612 assays assay NNS 613 621 strongly strongly RB 622 629 suggest suggest VBP 630 634 that that IN 635 639 this this DT 640 648 sequence sequence NN 649 657 mediates mediate VBZ 658 661 the the DT 662 679 ionomycin-induced ionomycin-induced JJ 680 690 activation activation NN 691 693 of of IN 694 697 the the DT 698 702 TCRG TCRG NNP 703 711 enhancer enhancer NN 711 712 . . . 713 716 Our our PRP$ 717 724 studies study NNS 725 732 provide provide VBP 733 735 an an DT 736 747 explanation explanation NN 748 751 for for IN 752 753 a a DT 754 762 previous previous JJ 763 774 observation observation NN 775 779 that that IN 780 784 TCRG tcrg NN 785 789 mRNA mrna NN 790 796 levels level NNS 796 797 , , , 798 801 but but CC 802 805 not not RB 806 810 mRNA mrna NN 811 817 levels level NNS 818 821 for for IN 822 823 T t NN 824 828 cell cell NN 829 837 receptor receptor NN 838 843 alpha alpha NN 844 847 and and CC 848 853 -beta -beta NN 853 854 , , , 855 858 are be VBP 859 868 increased increase VBN 869 871 by by IN 872 881 ionomycin ionomycin NN 882 891 treatment treatment NN 891 892 . . .